Trevi Therapeutics Inc (TRVI)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.95B
Last updated: Nov 17, 2026 at 11:06 AM ET
Trevi Therapeutics Inc (TRVI) Stock Forecast
Analysts expect Trevi Therapeutics (TRVI) to earn -$0.50 per share in the fiscal year ending Dec 31, 2026. Of 11 analysts, 11 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$0.59.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 11 ratings average 1.82, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 18.2% |
| Buy | 9 | 81.8% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 11
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss.
- Fiscal year ending Dec 31, 2026
- -$0.50
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$0.59
- EPS consensus
- Next report
- Mar 15, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.50 | -$0.52 to -$0.47 | 8 |
| Dec 31, 2027 | -$0.59 | -$0.76 to -$0.39 | 10 |
Quarterly Estimates
The EPS consensus falls from -$0.15 for the quarter ending Dec 31, 2026 to -$0.16 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.15 | -$0.18 to -$0.12 | 14 |
| Mar 31, 2027 | -$0.16 | -$0.17 to -$0.15 | 2 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 1 upward and 5 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2027 | 1 | 5 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.48.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.50 | -$0.48 | -$0.48 | -$0.48 | -$0.48 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.59 | -$0.58 | -$0.58 | -$0.58 | -$0.58 | N/A |
| Quarter ending Mar 31, 2027 | -$0.16 | -$0.16 | -$0.16 | -$0.16 | -$0.16 | N/A |
Frequently Asked Questions About TRVI
What is the TRVI stock forecast?
Consensus analyst estimates put Trevi Therapeutics's EPS at -$0.50 for the fiscal year ending Dec 31, 2026. The consensus rating from 11 analysts is Buy.
How do analysts rate TRVI stock?
Of 11 analysts covering Trevi Therapeutics, 2 rate it Strong Buy, 9 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from TRVI next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.50, with estimates from -$0.52 to -$0.47 from 8 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.59, with estimates from -$0.76 to -$0.39 from 10 analysts.
How many analysts cover TRVI?
11 analysts rate Trevi Therapeutics stock, and 8 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
TRVI pages: Overview, Earnings, Forecast, Financials, Competitors